Tagged with BI

Spain Reig Jofre’s Ignasi Biosca outlines recent changes at the Spanish family-owned company, preserving its original ethos, portfolio development and internationalization plans. Can you update us on some of the recent changes at Reig Jofre? “The family still maintains 72 percent of the shares of the company so the original corporate…

UK Dr. Geoffrey Guy, chairman and founder of cannabinoid medicine pioneer, GW Pharma, outlines the potential benefits that Brexit could bring to the UK’s life sciences industry and the evolution of his company. Unlike many of your peers, you are very optimistic about Brexit. What opportunities do you believe Brexit will…

Hong Kong Gene Shigekawa, managing partner of MAZ World, shares their recent move to the Hong Kong Science and Technology Park (HKSTP) in 2017, the revolutionary ostrich-derived antibody they hope to further develop and commercialize, the strengths of Hong Kong as a biotech base for start-ups, and the huge potential for their…

Canada As cannabis in Canada cruises towards legalization, Pharma giants race for patented products.   Big Pharma is establishing a significant cannabis presence in Canada with registered patents in advance of legalization. As cannabis-plant-based drugs proliferate globally, opportunities for new technologies and revolutionary advances in health and wellness sciences will continue…

GSK KaNDy Therapeutics, a UK-based biotech has raised £25 million to finance the Phase 2b trial of their breakthrough product in Women’s Health. Our investors and the KaNDy management team are united by the common belief that NT-814 has the potential to be a transformational treatment for the millions of women worldwide…

Hong Kong Professor Hon-Ming Lam, a renowned scientist specializing in soybean genomics, shares his passion for his research, the importance of soybeans to China’s future environmental and growth sustainability, his insights on Hong Kong’s ambition to become an innovation and technology hub, and his perspective on how government, industry and academics should…

Hong Kong Professor Justin Wu, chief operating officer of the Chinese University of Hong Kong (CUHK) Medical Center, shares his professional background and interest in gastroenterology, his insights into the research and commercialization environment in Hong Kong, and his hope for government, industry and academia to work together to propel Hong Kong…

UK Thomas Broeer, managing director UK and Ireland for Aurobindo, has been at the helm of Aurobindo’s UK subsidiary, Milpharm Limited for almost two years and here discusses the UK market’s strengths, the potential impact of Brexit on the pharmaceutical industry and the pricing structures in place in the UK.  …

UK Three years into his role as general manager of Sobi’s UK and Republic of Ireland operations, Neil Dugdale introduces the scope of operations of the Swedish rare disease player to our audience, highlighting the company’s unique positioning in working closely with patient groups to drive forward better understanding of unmet…

UK Heading FUJIFILM Diosynth Biotechnologies’ operations globally, Steve Bagshaw speaks out about the excellence of science in the UK and how it fits the company’s plans to build up a solid presence in the development and manufacturing of new advanced treatments. He further explains how the company has been able to…

Turkey Hakan Koçak, CEO–general manager of Koçak Farma, a company with 47 years in the pharmaceutical industry and the biggest production facility in Turkey, gives a thorough insight into Koçak Farma’s background, with their ground-breaking biosimilars as the leaders in the area of oncology with 85 products approved in Turkey, in…

UK Chief Executive since 2011, Peter Coleman introduces Cobra Biologics and highlights challenges both domestically and globally in the biotech space for CDMOs; he addresses funding opportunities within the public and private sector and Cobra Biologics’ ambitious plans for 2022. Can you please introduce Cobra Biologics to our international readers? “The…